2/6
10:34 am
pmn
Promis Neurosciences (NASDAQ:PMN) had its price target lowered by analysts at Guggenheim from $125.00 to $35.00. They now have a "buy" rating on the stock.
Low
Report
Promis Neurosciences (NASDAQ:PMN) had its price target lowered by analysts at Guggenheim from $125.00 to $35.00. They now have a "buy" rating on the stock.
2/4
05:28 pm
pmn
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 [Canadian Business Journal (Canada)]
High
Report
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 [Canadian Business Journal (Canada)]
2/4
04:05 pm
pmn
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
High
Report
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
1/30
08:00 am
pmn
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
High
Report
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
12/18
07:30 am
pmn
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
Medium
Report
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
12/10
07:30 am
pmn
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
Medium
Report
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
12/1
09:05 am
pmn
Promis Neurosciences (NASDAQ:PMN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Promis Neurosciences (NASDAQ:PMN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/1
07:30 am
pmn
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
Medium
Report
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
12/1
07:28 am
pmn
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference [Canadian Business Journal (Canada)]
Medium
Report
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference [Canadian Business Journal (Canada)]
12/1
07:00 am
pmn
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
Medium
Report
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
11/29
03:35 am
pmn
Promis Neurosciences (NASDAQ:PMN) was downgraded by analysts at
Wall Stre
Medium
Report
Promis Neurosciences (NASDAQ:PMN) was downgraded by analysts at
Wall Stre
11/24
08:00 am
pmn
ProMIS Neurosciences Announces Reverse Stock Split
Medium
Report
ProMIS Neurosciences Announces Reverse Stock Split
11/21
08:05 am
pmn
Promis Neurosciences (NASDAQ:PMN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Low
Report
Promis Neurosciences (NASDAQ:PMN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
11/18
09:34 am
pmn
Promis Neurosciences (NASDAQ:PMN) had its price target lowered by analysts at Guggenheim from $6.00 to $5.00. They now have a "buy" rating on the stock.
Medium
Report
Promis Neurosciences (NASDAQ:PMN) had its price target lowered by analysts at Guggenheim from $6.00 to $5.00. They now have a "buy" rating on the stock.
11/15
07:05 pm
pmn
Can ProMIS Neurosciences (NASDAQ:PMN) Afford To Invest In Growth? [Yahoo! Finance]
High
Report
Can ProMIS Neurosciences (NASDAQ:PMN) Afford To Invest In Growth? [Yahoo! Finance]
11/12
07:28 am
pmn
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights [Canadian Business Journal (Canada)]
Low
Report
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights [Canadian Business Journal (Canada)]
11/12
07:00 am
pmn
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
Medium
Report
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights